Pediatric Exclusivity: 36% Of Studies Lead To Significant New Labeling – FDA
Executive Summary
Studies conducted under the pediatric exclusivity program resulted in significant new dosing or safety information 36% of the time, according to a study published in the Journal of the American Medical Association Aug. 20